Epigenetic age measured as a trial endpoint for supplement and drug sponsors
TL;DR Clockbench is a contract lab that measures epigenetic age, using DNA methylation clocks, in blood samples from clinical studies. Nutraceutical, ayurveda and drug companies running trials in India pay per sample. It sells careful measurement to sponsors, not personal wellness advice to consumers.
Indian consumers can already buy an epigenetic age test. One large genomics lab's test sells on an online pharmacy for ₹52,000[1], and a market report lists at least four more Indian brands[2]. The weak point is the science behind tracking one person over time. A 2022 study in an ageing research journal found that technical noise moved results by up to 9 years between repeat runs of the same sample across six popular clocks[3]. So if your wellness plan changes every time your number moves a few years then it's partly chasing noise.
Meanwhile India's nutraceutical makers, a market of roughly $8–10 billion in 2023[4], face pressure to back their claims with studies. Few Indian labs offer trial-grade ageing measures.
What it does, in regulatory terms: research measurement only. Results are exploratory study endpoints reported to sponsors, not diagnoses or health advice to participants. Each study still needs ethics committee approval, and drug trials fall under the New Drugs and Clinical Trials Rules 2019[5].
The seed was a consumer service that tunes wellness plans to repeated epigenetic tests. I reframed it, because the consumer shelf is crowded and single-person tracking is unreliable. Group averages in a well-designed trial are a much better use of the same measurement.
Clockbench runs methylation arrays on study samples and reports several published clocks, using the more stable principal-component versions the 2022 study proposed[3]. Every batch is blinded, with repeat samples and controls built in, so a sponsor can show reviewers the measurement error alongside the result. The lab also advises on sample size before a study starts, since a weak trial design wastes everyone's money.
Participants never pay. The buyers are companies running studies - nutraceutical and ayurveda brands testing an ageing or metabolic claim, contract research organisations, and drug companies adding an exploratory endpoint. Academic groups are a smaller second buyer. My assumption is a per-sample price of ₹12,000–25,000 for trial work, well below the consumer retail price, with a minimum batch size.
Consumer ageing tests reached Indian online pharmacies in the last few years[1][2], which raised brand interest in "biological age" claims. A forecast puts India's biological age testing market at US$67.63 million in 2026, with pharma and biotech buyers 5% of it[2]. The reliability work published in 2022[3] gives labs a defensible way to report results.
The narrowest figure I found is from a market research firm, which estimates India's biological age testing market at US$58.4 million in 2025 (about ₹565 Cr), with DNA methylation clocks 45% of it by method, and research institutions plus pharma and biotech together 13% of buyers[2]. That puts the research slice near ₹70 Cr, my arithmetic on a single commercial estimate. Treat it as a rough ceiling.
A large genomics lab sells an epigenetic age test to consumers in India[1]. Other Indian DNA and nutrition brands also offer biological age products, some through US lab partners[2]. One US epigenetics lab describes its database as the world's largest epigenetic one and sells research services for trials[6]. No Indian lab that I found positions itself as a trial endpoint service with published error rates. That is the gap.
| Difficulty | Hard (56/100) |
| Starting capital | ₹2.5–4.5 Cr |
| Time to launch | 12–18 months |
The lab equipment and array costs are real, and quality systems take time. The hardest parts are proving your measurement is repeatable to sponsors and convincing the first brands to run a properly sized trial rather than a small marketing study dressed up as science.
Your lab needs no product licence, but every study you work on is regulated.
Building this outside India? The categories above usually have a local equivalent, so check with your own regulator.
Don't let AI turn a group result into a health claim for any one person. These are exploratory study endpoints, nothing more.
Want to work out the AI layer for Clockbench? Talk to Yash →
Here's what can go south -
I think this fits a founder with molecular lab and clinical research experience who is comfortable reporting results sponsors do not like. If you want a consumer brand then look elsewhere. Before buying equipment, prove that three sponsors will commission a pilot study and accept the lab's terms on how results may be quoted.
Plan for roughly ₹2.5–4.5 Cr, mostly array equipment, bioinformatics staff and validation runs. The free kit has the line-by-line capital breakdown.
The sponsor holds trial permission under CDSCO's 2019 rules. You need ethics approval per study and DPDP compliance.
Yes, sponsors run studies globally. Check your local clinical trial rules and lab accreditation before you bid.
The free Clockbench validation kit has the line-by-line capital breakdown, the effort scoring, the ethics, trial and data-protection checklist, a 14-day validation sprint with pass/fail targets, a 90-day launch plan, 10 interview questions for trial sponsors, and 5 assumptions to test. Download the kit →
Thinking about building Clockbench or something close to it? The make-or-break work is showing sponsors a repeatable measurement and holding firm on how they may quote it. If you need a hand, you know where to find me. Talk to Yash →
For illustration only. Names are fictional and ideas hypothetical; sourced facts are real but may be out of date. Nothing here is legal, financial or professional advice, and Yash Khatri is not personally liable for any use of it. Read the full disclaimer.